ESR statement on the stepwise development of imaging biomarkers

Insights into Imaging

Volumn 4, Issue 2, 2013, Pages 147-152

[No Author Info available]

Author keywords

Imaging biomarkers; Qualification; Validation

Indexed keywords

EID: 84875675693     PISSN: None     EISSN: 18694101     Source Type: Journal    
DOI: 10.1007/s13244-013-0220-5     Document Type: Article

References (46)

1. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3): 89-95.
2. Waterton JC, Pylkkanen L (2012) Qualification of imaging biomarkers for oncology drug development. Eur J Cancer 48(4): 409-415.
3. European Society of Radiology (2010) White paper on imaging biomarkers. Insights Imaging 1(2): 42-45.
4. Wagner JA, Williams SA, Webster CJ (2007) Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 81(1): 104-107.
5. Marti Bonmati L, Alberich-Bayarri A, Garcia-Marti G, Sanz Requena R, Pérez Castillo C, Carot Sierra JM, Herrera M (2012) Imaging biomarkers, quantitative imaging, and bioengineering. Radiol 54(3): 269-278.
6. Lewin M, Poujol-Robert A, Boelle PY et al (2007) Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 46(3): 658-665.
7. Luciani A, Vignaud A, Cavet M et al (2008) Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology 249(3): 891-899.
8. Bonekamp S, Torbenson MS, Kamel IR (2011) Diffusion-weighted magnetic resonance imaging for the staging of liver fibrosis. J Clin Gastroenterol 45(10): 885-892.
9. Leitao HS, Doblas S, d'Assignies G, Garteiser P, Daire JL, Paradis V, Geraldes CF, Vilgrain V, van Beers BE (2012) Fat deposition decreases diffusion parameters at MRI: a study in phantoms and patients with liver steatosis. Eur Radiol 23(2): 461-467.
10. Le Bihan D, Urayama S, Aso T, Hanakawa T, Fukuyama H (2006) Direct and fast detection of neuronal activation in the human brain with diffusion MRI. PNAS 103(21): 8263-8268.
11. Xu J, Does MD, Gore JC (2011) Dependence of temporal diffusion spectra on microstructural properties of biological tissues. Magn Reson Imaging 29(3): 380-390.
12. Sinkus R, van Beers BE, Vilgrain V, DeSouza N, Waterton JC (2012) Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development. Eur J Cancer 48(4): 425-431.
13. Yablonskiy DA, Sukstanskii AL (2010) Theoretical models of the diffusion weighted MR signal. NMR Biomed 23(7): 661-681.
14. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 45(2): 228-247.
15. Padhani AR, Khan AA (2010) Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Target Oncol 5(1): 39-52.
16. Bossuyt PM, Reitsma JB, Bruns DE et al (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Radiology 226(1): 24-28.
17. Barnhart HX, Barboriak DP (2009) Applications of the repeatability of quantitative imaging biomarkers: a review of statistical analysis of repeat data sets. Transl Oncol 2(4): 231-235.
18. Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11(2): 102-125.
19. Taouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254(1): 47-66.
20. Kwee TC, Takahara T, Koh DM, Nievelstein RA, Luijten PR (2008) Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. J Magn Reson Imaging 28(5): 1141-1148.
21. Ivancevic MK, Kwee TC, Takahara T et al (2009) Diffusion-weighted MR imaging of the liver at 3. 0 Tesla using tracking only navigator echo (TRON): a feasibility study. J Magn Reson Imaging 30(5): 1027-1033.
22. Zussman B, Jabbour P, Talekar K, Gorniak R, Flanders AE (2011) Sources of variability in computed tomography perfusion: implications for acute stroke management. Neurosurg Focus 30(6): E8.
23. Rajaraman S, Rodriguez JJ, Graff C et al (2011) Automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques. Magn Reson Imaging 29(5): 668-682.
24. Wagner M, Doblas S, Daire JL, Paradis V, Haddad N, Leitao H, Garteiser P, Vilgrain V, Sinkus R, van Beers BE (2012) Diffusion-weighted MR imaging for the regional characterization of liver tumors. Radiology 264(2): 464-472.
25. Moffat BA, Chenevert TL, Lawrence TS et al (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. PNAS 102(15): 5524-5529.
26. Yang X, Knopp MV (2011) Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging: a review. J Biomed Biotechnol 732848: 1-12.
27. Buckley DL (2002) Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 47(3): 601-606.
28. Michoux N, Huwart L, Abarca-Quinones J et al (2008) Transvascular and interstitial transport in rat hepatocellular carcinomas: dynamic contrast-enhanced MRI assessment with low- and high-molecular weight agents. J Magn Reson Imaging 28(4): 906-914.
29. Leach MO, Brindle KM, Evelhoch JL et al (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92(9): 1599-1610.
30. Buckler AJ, Schwartz LH, Petrick N et al (2010) Data sets for the qualification of volumetric CT as a quantitative imaging biomarker in lung cancer. Opt Express 18(14): 15267-15282.
31. Huwart L, Sempoux C, Vicaut E et al (2008) Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135(1): 32-40.
32. Friedrich-Rust M, Nierhoff J, Lupsor M et al (2012) Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 19(2): e212-e219.
33. Degos F, Perez P, Roche B et al (2010) Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 53(6): 1013-1021.
34. Chenevert TL, Galban CJ, Ivancevic MK et al (2011) Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies. J Magn Reson Imaging 34(4): 983-987.
35. Lee YC, Fullerton GD, Baiu C, Lescrenier MG, Goins BA (2011) Preclinical multimodality phantom design for quality assurance of tumor size measurement. BMC Med Phys 11: 1.
36. Szegedi M, Rassiah-Szegedi P, Fullerton G, Wang B, Salter B (2010) A proto-type design of a real-tissue phantom for the validation of deformation algorithms and 4D dose calculations. Phys Med Biol 55(13): 3685-3699.
37. Wilhjelm JE, Jespersen SK, Falk E, Sillesen H (2006) The challenges in creating reference maps for verification of ultrasound images. Ultrasonics 4(Suppl 1): e141-e146.
38. Wang TJ (2011) Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 123(5): 551-565.
39. Polonsky TS, McClelland RL, Jorgensen NW et al (2010) Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 303(16): 1610-1616.
40. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1): 122S-150S.
41. Cummings J, Ward TH, Dive C (2010) Fit-for-purpose biomarker method validation in anticancer drug development. Drug Discov Today 15(19-20): 816-825.
42. Richter WS (2006) Imaging biomarkers as surrogate endpoints for drug development. Eur J Nucl Med Mol Imaging 33(Suppl 1): 6-10.
43. Woodcock J, Woosley R (2008) The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59: 1-12.
44. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646-674.
45. Soloviev D, Lewis D, Honess D, Aboagye E (2012) [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer 48(4): 416-424.
46. Nguyen QD, Challapalli A, Smith G, Fortt R, Aboagye EO (2012) Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11. Eur J Cancer 48(4): 432-440.